Summary & Overview
CPT 0469U: IriSight CNV Whole Genome Fetal Analysis
CPT code 0469U designates the IriSight™ CNV Analysis, a proprietary whole genome sequencing–based laboratory test from Variantyx Inc. used to detect fetal chromosomal abnormalities, including copy number variants and structural changes, with integrated parental comparison and assessment for maternal cell contamination. As a PLA code, 0469U identifies a single manufacturer-specific assay and matters nationally because it defines a unique billing pathway for an advanced prenatal genetic diagnostic service that may impact coverage policies and payment practices across payers.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose and laboratory setting for the test, followed by benchmarks and policy context relevant to proprietary genetic assays. The publication summarizes coding specifics, payer coverage patterns, clinical indications and service utilization considerations, and where available, reimbursement and billing nuances tied to PLA coding. The content is intended to inform clinicians, laboratory administrators, and policy analysts about the code’s scope, typical use-case, and implications for billing and coverage at a national level.
Billing Code Overview
CPT code 0469U is a Proprietary Laboratory Analyses (PLA) code that applies solely to the IriSight™ CNV Analysis from Variantyx Inc. This test performs whole genome sequence analysis on fetal samples to detect chromosomal abnormalities, including copy number variants and other structural changes. The diagnostic report integrates sequencing findings and, when available, compares fetal results against maternal and paternal samples to assist in variant identification and categorization while accounting for potential maternal cell contamination.
-
Service Type: Genetic diagnostic testing using whole genome sequencing and specialized bioinformatic analysis for fetal chromosomal abnormality detection
-
Typical Site of Service: Clinical or commercial molecular diagnostic laboratory; specimens originate from prenatal/fetal sampling (lab-performed testing)
Clinical & Coding Specifications
Clinical Context
A pregnant patient undergoes genetic evaluation after abnormal prenatal screening or ultrasound findings suggestive of chromosomal imbalance (for example, fetal structural abnormalities, growth restriction, or increased risk on noninvasive prenatal testing). A maternal-fetal medicine specialist or obstetrician orders the IriSight™ CNV Analysis (0469U) when whole genome sequencing-based copy number variant (CNV) analysis on a fetal sample (amniotic fluid, chorionic villus sample, or fetal blood) is needed to detect deletions, duplications, aneuploidies, and other structural chromosomal abnormalities. The clinical workflow includes sample collection at the outpatient or hospital ambulatory setting; specimen shipment to Variantyx Inc.; laboratory receipt and whole genome sequencing with bioinformatic CNV calling; integration of fetal results with available parental samples to determine inheritance and to assess for maternal cell contamination; generation of a diagnostic report summarizing clinically significant CNVs and interpretation; and transmission of results to the ordering clinician for counseling and management decisions. Typical sites of service are outpatient clinics, maternal-fetal medicine centers, hospital ambulatory surgical units, and specialized prenatal diagnostic laboratories. Indications include suspected chromosomal disorders, abnormal ultrasound findings, family history of chromosomal rearrangements, or confirmation after abnormal screening tests.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no other modifier applies to the professional or technical aspects of the service |
26 | Professional component | Use when billing only the interpretation/reporting component separate from the lab technical services (rare for PLA codes billed by the performing lab) |
52 | Reduced services | Use when testing is partially performed or a limited analysis is completed and documented |
53 | Discontinued procedure | Use when testing cannot be completed due to specimen failure or preanalytic loss and documentation supports discontinuation |
62 | Two surgeons | Not typically used for lab procedures; include only if complex multi-operator specimen procurement billing applies |
78 | Return to OR for related procedure following initial procedure | Not routinely applicable to the lab test itself; used if an operative return is required for sample procurement |
80 | Assistant surgeon | Not applicable to the lab test; may apply to the clinician performing invasive sample collection if assistant billing is required |
82 | Assistant surgeon (when qualified resident unavailable) | Same clinical caveat as 80 for sample procurement scenarios |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services | Use when a qualified nonphysician practitioner furnishes billable professional services related to sample collection or counseling |
QK | CLIA waived testing oversight by nonphysician technologist | Use only when applicable laboratory personnel credentialing affects billing for the test's technical component |
QX | CLIA waived test performed by a certified lab technician | Use when billing differentiates personnel performing the test under CLIA rules (rare for high-complexity PLA assays) |
QY | CLIA waived test performed under physician supervision | Similar to QK/QX; use if billing requires identification of supervisory arrangement |
TC | Technical component | Use when billing only the laboratory technical component of testing separate from professional interpretation |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 208D00000X | Maternal-Fetal Medicine (Perinatology) | Specialists who commonly order prenatal genetic testing and interpret results |
| 207Q00000X | Obstetrics & Gynecology | Ordering clinicians for prenatal diagnostic evaluation |
| 208000000X | Clinical Genetics | Clinical geneticists who evaluate and counsel on CNV findings |
| 2084P0800X | Laboratory Genetics & Genomics | Laboratory specialists overseeing genomic testing and interpretation |
| 394AGP0000X | Genetic Counseling | Genetic counselors who coordinate testing, obtain consent, and provide patient counseling |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
O35.2XX0 | Maternal care for (suspected) chromosomal abnormality in fetus, not applicable or unspecified | Use when prenatal testing is ordered for suspected fetal chromosomal anomalies |
Z36 | Encounter for antenatal screening of mother | Use when ordered as part of an antenatal screening/diagnostic evaluation workflow |
R94.5 | Abnormal results of genetic studies | Use when prior screening or tests yield abnormal genetic findings prompting comprehensive CNV analysis |
Q99.9 | Chromosomal abnormality, unspecified | Used when fetal chromosomal abnormality is identified or suspected and further characterization is needed |
O28.89 | Abnormal findings on antenatal screening of mother, other specified | Broad code for abnormal prenatal screening results leading to diagnostic testing |
Z31.83 | Encounter for pregnancy testing and childbirth, genetic counseling for pregnancy | Use when genetic counseling is provided in conjunction with ordering 0469U |
Q90.9 | Down syndrome, unspecified | Example of a specific chromosomal aneuploidy that CNV analysis can detect or further characterize |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
59000 | Sampling of amniotic fluid (amniocentesis) | Performed to obtain fetal DNA sample prior to 0469U testing when indicated |
59160 | Percutaneous umbilical cord blood sampling (PUBS) | Alternative fetal sampling method when amniocentesis or CVS is not suitable; provides fetal blood for genomic testing |
59840 | Induced labor for fetal anomaly or intrauterine fetal demise | May be part of clinical management following diagnostic results; related downstream obstetric procedure |
81420 | Molecular pathology procedure, genomic sequence analysis (eg, whole exome) | Other sequencing codes that may be ordered in parallel or as alternative genomic analyses; complementary test in diagnostic workflow |
88291 | Chromosome analysis, constitutional (karyotype), binned or banding | Traditional cytogenetic test that may be performed alongside or prior to 0469U for structural chromosome evaluation |
88237 | FISH, using probe(s) for specific chromosomal region(s) | Targeted test to confirm or clarify copy number findings identified by genome-wide CNV analysis |